Mission Bio raises $30M series B to expand Tapestri’s reach

Precision genomics company Mission Bio Inc. (South San Francisco, Calif.) raised $30 million in an untranched series B round from Agilent Technologies (NYSE:A), Cota Capital, Laboratory Corp. of America Holdings (NYSE:LH), LAM Research Capital and Mayfield to scale up its single-cell DNA analysis platform, dubbed Tapestri, and expand into global markets.

Mission Bio markets Tapestri to drug developers and academic medical centers that use the platform to detect genetic heterogeneity in cancers and develop precision medicines for blood cancers and solid tumors, and to detect on-target and off-target effects of gene editing...